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Summary Introduction
Velo-cardio-facial syndrome (VCFS; MIM 19243) is aVelo-cardio-facial syndrome (VCFS) is a relatively common
genetic disorder with an estimated frequency of 1/4,000developmental disorder characterized by craniofacial anom-
live births (Burn and Goodship 1996). Most VCFS casesalies and conotruncal heart defects. Many VCFS patients
are sporadic, but, when inherited, it has an autosomalhave hemizygous deletions for a part of 22q11, suggesting
dominant pattern of transmission. This disorder is char-that haploinsufﬁciency in this region is responsible for its
acterized by conotruncal heart defects, cleft palate,etiology. Becausemost cases of VCFS are sporadic, portions
learning disabilities, and mild facial dysmorphology.of 22q11 may be prone to rearrangement. To understand
Since its original description in 1978 (Shprintzen et al.the molecular basis for chromosomal deletions, we deﬁned
1978), ú40 physical anomalies, including hypocal-the extent of the deletion, by genotyping 151 VCFS patients
cemia, blood-vessel anomalies such as tortuous retinaland performing haplotype analysis on 105, using 15 consec-
vessels, thrombocytopenia, mental retardation, and hy-utive polymorphic markers in 22q11. We found that 83%
potonia have been described to occur in association withhad a deletion and ú90% of these had a similar Ç3 Mb
VCFS (Goldberg et al. 1993). A newly recognized ﬁnd-deletion, suggesting that sequences ﬂanking the common
ing associated with VCFS is the development of severebreakpoints are susceptible to rearrangement. We found no
psychiatric illness in patients as they reach adulthoodcorrelation between the presence or size of the deletion and
(Goldberg et al. 1993; Chow et al. 1994; Pulver et al.the phenotype. To further deﬁne the chromosomal
1994; Karayiorgou et al. 1995; Papolos et al. 1996;breakpoints among the VCFS patients, we developed so-
Carlson et al. 1997). The clinical features of VCFS over-matic hybrid cell lines froma set of VCFS patients. An 11-kb
lap signiﬁcantly with those of DiGeorge syndromeresolution physical map of a 1,080-kb region that includes
(DGS) (DiGeorge 1965). DGS includes the anomalies ofdeletion breakpoints was constructed, incorporating genes
VCFS, and the patients also manifest thymic aplasia orand expressed sequence tags (ESTs) isolated by the hybrid-
hypoplasia and severe hypocalcemia (Goldberg et al.ization selection method. The ordered markers were used
1985; Stevens et al. 1990). Both VCFS and DGS areto examine the two separated copies of chromosome 22 in
associated with interstitial deletions of 22q11 (de lathe somatic hybrid cell lines. In some cases, we were able
Chapelle et al. 1981; Greenberg et al. 1988; Driscoll ettomap the chromosome breakpoints within a single cosmid.
al. 1992a, 199b; Scambler et al. 1992).A 480-kb critical region for VCFS has been delineated,
The relatively high incidence of sporadic cases ofincluding the genes for GSCL, CTP, CLTD, HIRA, and
VCFS associated with 22q11 deletions suggests that spe-TMVCF, as well as a number of novel ordered ESTs.
ciﬁc regions in 22q11 might be susceptible to rearrange-
ments. To ascertain the molecular basis for the deletions,
we used a set of 15 highly polymorphic markers located
in 22q11 to genotype 151 VCFS patients and to perform
haplotype analysis on 105. Loss-of-heterozygosity anal-
ysis with these markers revealed that 83% of the patientsReceived March 6, 1997; accepted for publication June 23, 1997.
Address for correspondence and reprints: Dr. Bernice Morrow, De- had an interstitial deletion. The patients who had dele-
partment of Molecular Genetics, Albert Einstein College of Medicine, tions could be classiﬁed into three classes. More than
1300 Morris Park Avenue, Bronx, New York 10461. E-mail: morrow 90% of them had a large, 3-Mb deletion. Most of the
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0002-9297/97/6103-0020$02.00 the rest contained unique nested deletion breakpoints.
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We were not able to make any correlations between the alleles, as well as the frequency of heterozygosity of each
marker, were determined by analysis of DNA from asize of the deletion and the severity of the syndromic
manifestations. number of normal relatives of VCFS patients. To deﬁne
the deletion at the individual patient level, we conductedTo more precisely define the chromosome
breakpoints, we developed a high-resolution physical detailed haplotype analysis on 105 patients and their
parents. The genotype of the patient and parents, forand transcript map within 22q11, containing a set of
deletion breakpoints. Somatic hybrid cell lines were de- each of the markers, was determined. The haplotypes
of the parents were deduced from the genotype of theveloped from a subset of the patients. By separating the
two copies of chromosome 22 in the somatic hybrid cell patient. Failure to inherit an allele from one of the par-
ents was reﬂected by a loss of heterozygosity for thatlines, we were able to utilize all of the PCR based mark-
ers, including simple tandem repeat polymorphic (STRP) particular locus.
markers and sequence-tag site (STS) markers that were
Hybridization Selectiondeveloped during construction of the physical map, to
deﬁne the deletion endpoints. On the basis of the unique A composite short-fragment cDNA library prepared
from RNA from a total fetal abortus (8–10 wk gesta-nested deletion endpoints in the patients, we were able
to identify for VCFS a critical region that is estimated to tion), fetal brain, and four adult tissues (brain, spleen,
testes, and thymus) was used (Parimoo et al. 1991; Sirot-be 480 kb in size. The critical region for VCFS contains
several recently discovered genes and ESTs. kin et al. 1996, 1997a, and 1997b). The YACs Y20E9,
Y5All, and R10BE5 (Collins et al. 1995; Morrow et al.
1995) were used separately as substrates to selectMaterial and Methods
cDNAs. The DNAs from the six-member fosmid contig
Preparation of DNA from VCFS Patients for Deletion consisting of H8-68, A4-73, A11-22, A9-100, C5-94,
Analysis and E2-21 were pooled and used as a substrate for the
selection. Forty independent clones from each selectionEach of the patients met the diagnostic criteria for
were sequenced by use of linker primers, by automatedVCFS, including velo-pharyngeal insufﬁciency, cleft of
sequencing machines (ABI 377), after PCR ampliﬁcationthe secondary palate, developmental delay, characteris-
and cloning into the bacteriophage lambda GT10 (Pari-tic facies, learning disabilities, and slender tapered digits,
moo et al. 1991). After sequence analysis, clones thatamong others (Shprintzen et al. 1978; Goldberg et al.
contained overlapping sequence were assembled into1993). We found that 61% of the VCFS patients had a
cDNA contigs. STSs were developed from the sequenceheart or major-vessel defect. Genomic DNA was pre-
of the cDNA contigs and were used for PCR analysis.pared from blood or buccal scrapings from each of the
VCFS patients and family members, by use of the Pure-
End-Speciﬁc Sequence-Tagged Sitesgene protocol (Gentra). The blood samples from each
The DNA from each cosmid clone was puriﬁed onof the individuals in this study were collected with the
Qiagen T-100 columns (Qiagen) and was used directlyassistance of many genetic counselors, physicians, and
for end sequencing with T3 and T7 vector primers, byscientists, through an Internal Review Board–approved
use of an ABI 377 automated sequencing machine. Afterprogram.
sequence analysis, a homology search of the GenBank/
Genetic Markers and Genotype and Haplotype EMBL database was performed by use of the computer
Analysis programs BLASTN and BLASTX (National Center for
Biotechnology Information). Primer pairs were devel-Fifteen STRP genetic markers were used for genotyp-
ing. Eleven of these markers (D22S420, D22S427, oped (by the PRIMER program) from unique genomic
sequences. The PCR conditions used for all of the prim-D22S941, D22S944, D22S264, D22S311, D22S306,
D22S308, D22S425, D22S303, and D22S257) have ers were one cycle at 94C for 2 min, 35 cycles of 94C
for 30 s, 58C for 30 s, and 72C for 30 s, and 1 cyclebeen described elsewhere (Morrow et al. 1995). A new
set of primers for D22S944 was developed because of a at 72C for 2 min, with use of standard PCR reaction
mixture (Perkin-Elmer).sequence polymorphism corresponding to one of
the primers (P. Bridge, personal communication). The
Construction of a PAC/Cosmid Contig in 22q11four new STRP markers—D22S1638, D22S1648,
D22S1623, and D22S1709—were developed from fos- The high-resolution physical map was generated by
use of cosmid clones from the LL22NC03 cosmid librarymid clone A11-22 and cosmid clones c443, 36F3, and
107D7, respectively, as described elsewhere (Morrow et and a genomic PAC library provided by Dr. P. DeJong
(Roswell Polytechnical College and Institute, Buffalo).al. 1995). The methodology to genotype the DNA from
patients and family members has been described else- The libraries were arrayed on high-density griddedmem-
branes, and the DNAs were screened with pools of 5–where (Morrow et al. 1995). The size and number of
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Table 1
Markers in 22q11
No. of
Name Primer Sequence Alleles Heterozygosity
GACAACAGCAAATTGCACATT
D22S1638 9 .78
TCACGCCACTACCCTCCAG
AGTTGTCAGATGCCTAAGAGA
D22S1648 5 .33
CAGATGCTTCAGGAGAAGTG
CGACCATAACTACTGAAAATAAAGG
D22S944N 9 .68
ATCCCATGCTCCTCCCCAT
AGGTAAATCTCATACCATGTAAAT
D22S1623 6 .64
CACAACTCCTGGGCTCAAGCT
CTCTTCCAAGTTCAGTGCTCT
D22S1709 10 .73
CACTTCAGCAAGAACAGCAGA
8 32P-radiolabeled STSs (Random Primed DNA Label- fected relatives. Both the order of the markers and the
ing Kit; Boehringer Mannheim). The positive clones results from this analysis are shown in table 2. A subset
were isolated from their individual plates, and DNAwas of the patients were genotyped earlier with 11 of the
prepared (Qiagen). Marker content of individual clones markers (Morrow et al. 1995). The level of heterozygos-
was established by PCR (50-ng template) under stan- ity among the unaffected family members was ú.5 for
dard conditions. The initial assembly yielded 10 sets of each of the 15 markers, except for D22S1648, which
overlapping bacterial clones. To connect the individual was .33. The levels of heterozygosity of the two most
cosmid/PAC contigs, STSs were developed from the ends proximal markers, D22S420 and D22S427, and of the
of the clones by direct sequence analysis and were used ﬁve most distal markers were indistinguishable between
as hybridization probes to rescreen the cosmid and PAC the VCFS patients and their unaffected relatives. For
library. This walking procedure was repeated until all each of the eight interstitial markers (D22S1638–
clone contigs were connected. D22S1709), the level of heterozygosity in the VCFS pa-
tients was considerably lower than that observed in the
Somatic-Cell Hybrids unaffected population (table 2). These results suggest
Somatic-cell hybrids were developed by fusion of Ep- that a large proportion of VCFS patients are hemizygous
stein-Barr virus–transformed lymphoblastoid cell lines for the region covered by the eight polymorphic mark-
from patients BM41, BM308, BM293, and BM8 from ers, and they placed the most commonly proximal
the Albert Einstein College of Medicine VCFS Patient breakpoint between D22S427 and D22S1638 and
Repository and patient G in the study by Levy et al. placed the most commonly distal breakpoint between
(1995), with either the hypoxanthine ribosyltransferase D22S1709 and D22S306/308.
(HPRT)–deﬁcient Chinese hamster–ovary ﬁbroblast
cell line GM 10658 (National Institute of General Medi-
Deﬁnition of Deletions in VCFS Patientscal Sciences [NIGMS]) (patients BM8 and BM75) or the
Haplotype analysis with the 15 polymorphic markersHPRT-deﬁcient Chinese hamster–ovary cell line CHTG49
was performed on 105 cases of VCFS with one or both(for patients BM41, BM308, and BM293 and patient
parents available. Among the 105 cases, ﬁve familiesG), as described elsewhere (Carlson et al. 1997). DNA
inherited the deletion; the rest of the cases were sporadic.was prepared and used for PCR analysis as described
We found that 90% of the patients had a similar deletionelsewhere (Carlson et al. 1997).
ﬂanked by D22S427 and D22S306/308, which was con-
sistent with the results obtained from genotype analysisResults
(table 2). We estimate the size of this interval to be 3
Genotype Analysis of VCFS Patients by Means of 15 Mb. We have identiﬁed 12 deleted VCFS patients who
STRP Markers had nested deletion endpoints. Nine VCFS patients had
a proximal breakpoint similar to that of the patientsFour new polymorphic markers were developed in the
with the 3-Mb deletion and had a nested distal deletion22q11 region (table 1). We used the 15 consecutive
breakpoint between the STRP markers D22S1623 andSTRP markers mapped to 22q11 to genotype 151 VCFS
D22S264. The deletion ﬂanked by D22S427 andpatients. For each marker, we compared the level of
heterozygosity in the patients with that in their unaf- D22S264 spans an interval with an estimated size of 1.5
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Table 2
Order of Markers and Results of Analysis
D22S420 D22S427 D22S1638 D22S941 D22S1648 D22S944 D22S1623 D22S264 D22S311 D22S1709 D22S306 D22S308 D22S425 D22S303 D22S257
No. of unaffected
relatives 89 164 192 194 137 193 114 191 96 81 92 90 81 70 72
No. of VCFS
patients 90 126 151 150 119 150 98 150 93 79 90 90 84 77 81
Heterozygosity in
unaffected
relatives .74 .6 .78 .7 .33 .68 .64 .83 .74 .73 .53 .51 .54 .81 .6
Heterozygosity in
VCFS patients .71 .56 .21 .15 .07 .17 .17 .22 .18 .27 .54 .59 .39 .64 .57
x2 .1 .49 63.38 64.18 24.73 54.22 33.36 67.59 39.98 23.6 .02 1.07 3.48 2.99 .12
P ú.95 ú.95 ú.95 ú.95 ú.95 ú.95 ú.95 ú.95
Mb (ﬁg. 1; Lindsay et al. 1993; Collins et al. 1995; balanced translocation with a breakpoint at 22q11 (Fu
et al. 1976). Elsewhere, this patient had been shown byMorrow et al. 1995).
One VCFS patient, whose cell line is referred to as FISH to have a unique nested distal deletion breakpoint
distal to the TUPLE1/HIRA gene and proximal to the‘‘GM00980’’ (NIGMS Cell Repository), carried an un-
D0832 cosmid (ﬁg. 2; Halford et al. 1993a). To further
deﬁne the distal deletion endpoint in GM00980, we per-
formed genotype analysis. One allele was present for
markers D22S420–D22S941 and two alleles, alleles 4
and 6 for D22S944. These results were consistent with
a chromosomal breakpoint between D22S941 and
D22S944.
We found that 17% of the patients did not have a
detectable deletion at the resolution of the 15 STRP
markers. In addition, we did not identify any nondeleted
cases VCFS that were inherited, suggesting that the non-
deleted sporadic cases of VCFS may be due to newmuta-
tions in 22q11, be due to genetic heterogeneity, or have
nongenetic causes.
Hybridization Selection of cDNAs from the Region
Flanked by D22S427 and D22S264
A hybridization selection methodology (Parimoo et
al. 1991) was used to isolate short-fragment cDNAs
corresponding to genes within the D22S427–D22S264
interval. The map position of each of the 12 genes and
18 ESTs, with respect to the genetic markers, is shown
in ﬁgure 1. Comparison of the sequences corresponding
to DNA on chromosome 22 with those in public data-
bases revealed that three of them corresponded to
known genes, IDD (integral membrane protein deleted
in DGS; Wadey et al. 1995), COMT (catechol-O-methyl
transferase; Grossman et al. 1992), HIRA (related to
yeast repressors of histone gene transcription, HIR1 and
HIR2; Lamour et al. 1995), and DGSI/ES2 (Lindsay et
Figure 1 Gene/EST map of the DGCR6–D22S933 interval in al. 1996; Gong et al. 1997). We isolated three distinct
22q11. Genes and ESTs (triangles) are indicated to the left and right, full-length cDNAs corresponding to three short-frag-
respectively, of the line representing the 22q11 region. TBX1 is a member ment cDNAs. One of them encodes a novel clathrin
of the T-box family of transcription factors (Chieffo et al. 1996). ‘‘COMT’’
heavy-chain gene (CLTD; Sirotkin et al. 1996); the sec-denotes the catechol-O-methyl transferase gene (Grossman et al. 1992).
ond encodes a new member of the catenin gene family,The genetic markers, D22S1638, D22S941, D22S1648, D22S944, and
D22S1623 are indicated (ovals). The critical region is boxed. which has armadillo repeats termed ‘‘ARVCF’’ (arma-
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Figure 2 High-resolution physical map of the DGCR6–D22S933 interval. The markers used to construct the physical map are indicated above the line representing chromosome
22q11. The orientation of the map is centromere to telomere, left to right. The polymorphic STSs (ovals), monomorphic STSs (squares), and gene or EST markers (triangles) are shown. All
of the STSs are numbered consecutively. The STSs derived from the ends of bacterial clones are denoted by an ‘‘X.’’ The blackened symbols denote markers that were tested with the
particular bacterial clones and that were present; and the unblackened symbols denote markers was not tested with the particular bacterial clone. The brackets under some of the markers
indicate regions where the markers could not be unambiguously ordered with respect to each other. The bacterial clones represented below the line consist of LL22NC03 cosmids and PACs
(‘‘P’’ followed by the address). Brackets within bacterial clones indicate a negative PCR result for that particular marker. The clones that form the minimal tiling path across the region are
boxed.
/9a35$$se17
09-02-97
18:27:24
ajhga
U
C-A
JH
G
625Carlson et al.: Molecular Deﬁnition of 22q11 Deletions
dillo repeat-containing gene deleted in VCFS; Sirotkin Repository and patient G from the study by Levy et al.,
with hamster ﬁbroblasts. Clones that retained chromo-et al. 1997b); and the third encodes a novel transmem-
brane protein with homologies to a cloned rat cDNA, some 22 were detected by use of D22S1604, a marker
that maps between D22S420 and D22S427 (ﬁg. 3) andtermed ‘‘TMVCF’’ (transmembrane protein deleted in
VCFS; Sirotkin et al., 1997a). A few of the other short- is not deleted in VCFS patients. To determine which
copy of chromosome 22 was present in each cell line,fragment cDNAs and cDNA contigs correspond to ESTs
that recently have been described elsewhere (Gong et the hybrids were genotyped with all or a subset of the
three STRP markers D22S420, D22S1638, andal. 1996); they include DGS-A (D22S1642, D22S1657,
D22S1652, and D22S1656) and DGS-D (D22S1633) D22S303 (data not shown). Appropriate hybrids were
screened with markers that are contained within the(Gong et al. 1996). In addition to all of these, we have
18 unique ESTs, each of which might correspond to D22S420–D22S306/308 region. The results of this
analysis are summarized in ﬁgure 3.genes in 22q11. We prepared primer pairs for each of
the genes and ESTs and used them for construction of STRP marker analysis of patients BM41, BM308, and
BM293 revealed that they had the commonly occurringthe high-resolution physical map.
3-Mb deletion ﬂanked by D22S427 and D22S306/308.
Construction of a High-Resolution Physical Map of the All three deletions occurred on the maternal chromo-
D22S427–D22S264 Interval some 22. Using STS markers, we determined that the
proximal breakpoint occurred between D22S1714 andWe constructed a high-resolution cosmid and PAC
contig, using a YAC contig (Collins et al. 1995; Morrow DGCR6 (Demczuk et al. 1996), in a gap of unknown
size in the physical map. The distal chromosomalet al. 1995) as the framework for the map shown in
ﬁgure 2. The map contains 125 cosmids, 6 fosmids, and breakpoint occurred between D22S935/D22S936 and
D22S1702. Since these distal markers are present within22 PACs. There are 99 STS markers, numbered consecu-
tively on the map, and they include 5 STRP genetic a single cosmid, we conclude that in these three patients
the distal breakpoints lie within the same 40-kb region.markers (D22S427 and D22S264 ﬂank the map), 38
gene or EST-based markers, and 56 monomorphic Included in this ﬁgure are the results of STRP marker
analysis of VCFS patient BM14, who represents a subsetmarkers. The cosmid sc11.1, used routinely for FISH
to detect 22q11 deletions (Lindsay et al. 1993, 1995a, of VCFS patients who had the same proximal chromo-
somal breakpoint as the majority of VCFS patients—1995b), was integrated into the physical map and was
found to be located between STRP markers D22S427 that is, between D22S427 and D22S1638—but had a
nested distal deletion endpoint between D22S1623 andand D22S1638. The cosmid 79H12 contains the gene
for the mitochondrial citrate-transport protein (CTP), D22S264, creating a deletion of Ç1.5 Mb.
A DGS patient termed ‘‘ADU’’ carries a t(2;22) bal-as well as the D22S75 locus that comprises the N25
probe commonly used to detect deletions in VCFS/DGS anced translocation that disrupts the 22q11 region (Au-
gusseau et al. 1986). The breakpoint junction has beenpatients (Goldmuntz et al. 1996). The cosmid and PAC
clones that constitute the minimal tiling path across the cloned (Budarf et al. 1995; Demczuk et al. 1995; Wadey
et al. 1995), and we have integrated the breakpointregion from DGCR6 to D22S933 are highlighted in ﬁg-
ure 2. The approximate size of the interval can be calcu- within the physical map (ﬁgs. 2 and 3). Patient BM8 was
shown by haplotype analysis to have a unique nestedlated by adding the average size of each of the clones
that constitute the minimal tiling path. There are eight proximal deletion between STRP markers D22S1638
and D22S941, the interval that contains the ADUPAC clones (120 kb 1 8 Å 960 kb) and three cosmid/
fosmid clones (40 kb 1 3 Å 120 kb). We estimate this breakpoint. To precisely deﬁne the breakpoint interval
of BM8, we developed somatic hybrid cell lines anddistance to be Ç1,080 kb. The map contains 99 STS
markers, and they provide an average resolution of 11 found that the proximal breakpoint of BM8 lies Ç5 kb
telomeric to that of ADU, within cosmid 39G4 (ﬁg. 2).kb (1,080 kb/99 markers).
A second DGS patient termed ‘‘G,’’ was found to have
Somatic-Cell Hybrid Analysis to Deﬁne the VCFS a unique proximal breakpoint, also telomeric to that of
Deletion Endpoints ADU (Levy et al. 1995). Analysis of somatic hybrid cell
lines from patient G revealed that the proximal dele-The resolution of the 15 STRP markers than span the
5 Mb of 22q11 region is 330 kb. To more precisely tion breakpoint occurred between D22S1697 and
D22S1621, both present on cosmid 79H12 (ﬁg. 3). Thedeﬁne the breakpoints in VCFS patients, we separated
the two copies of chromosome 22 by generating human- distal breakpoint of patient G was also unique, and it
occurred between the markers D22S311 and D22S1709,hamster somatic-cell hybrids. Somatic hybrid cell lines
were obtained by fusion of lymphoblastoid cells from both of which are present on the CEPH mega-YACs
792f9 and 861d9 (Collins et al. 1995; Morrow et al.patients BM41, BM308, BM293, BM8, and BM75 from
the Albert Einstein College of Medicine VCFS Patient 1995). On the basis of the analysis of patient G and
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Figure 3 Deﬁnition of the deletion endpoints in VCFS patients. All of the markers are shown above the line representing chromosome
22q11. The map is drawn to scale and was based on the YAC-contig physical map (Collins et al. 1995; Morrow et al. 1995). All of the markers
in the DGCR6–D22S933 interval are numbered consecutively (ﬁg. 2). Both the genetic markers a(circles) and the monomorphic STSs (squares)
are shown. The 3-Mb and 1.5-Mb deletions are indicated. The broken vertical lines denote various chromosomal breakpoints. The hatched
region represents the deleted interval determined by STS analysis for patients BM41, BM308, BM293, and BM8 and patient G (or STRP
analysis, for BM14). The critical region is boxed.
FISH, as well as genotype analysis of GM00980 (Hal- However, not all of the ú40 clinical ﬁndings associated
with VCFS (Goldberg et al. 1993) can be attributed toford et al. 1993a), the critical region for VCFS must lie
within the D22S1694–D22S944 interval. The size of a defect in neural crest cells. It is possible that some of
the associated anomalies of VCFS occur as the result ofthe critical region is estimated to be 480 kb and is based
haploinsufﬁciency or because of uncovering of recessiveon the minimal tiling path of four PACs—178M21,
mutations in additional genes outside the critical region238C15, 233H17, and 345B3 (ﬁg. 2). The proximal end
but are deleted in the great majority of patients. Forof this critical region is 120 kb distal to that of ADU.
example, the expression of the GpIbb gene, a gene thatVCFS patient BM75 was tested with 71 markers that
maps within the commonly deleted region but is outsidespan the 1,080-kb interval. All of these markers were
the critical region, is eliminated in one VCFS patientpresent on both the paternal and the maternal chromo-
affected with a rare bleeding disorder, termed ‘‘Bernard-some 22 (data not shown). These results show that
Soulier syndrome’’ (Budarf et al. 1995). It is possibleBM75 did not have a deletion that can be detected by
that a recessive mutation in the GpIbb gene is responsi-these 71 markers, which provide an average resolution
ble for the etiology of Bernard-Soulier syndrome in thisof 15 kb (1,080/71). Two other VCFS patients, exam-
patient.ined elsewhere (Carlson et al. 1997), also did not have
We have genotyped 151 well-diagnosed VCFS pa-a detectable deletion in 22q11.
tients and have performed haplotype analysis on a large
number of them, using 15 highly polymorphic markers.Discussion
Four classes of patients were identiﬁed: nondeleted pa-
Many of the tissues and structures affected in VCFS/ tients, patients with a 3-Mb deletion, patients with a
DGS derive from the pharyngeal arches of the devel- 1.5-Mb deletion, and patients with unique deletions.
oping embryo. During embryonic development, neural There was no correlation between the phenotype and
crest cells migrate into the pharyngeal arches and partici- the presence or size of the deletion in this patient popula-
pate in the formation of the craniofacial region, the tion.
neck, and the conotruncal region of the heart. It is possi- To detect unique small deletions among the patients
ble that a defect in either neural crest cells or their migra- who did not have a deletion detectable by haplotype
tion is responsible for the main clinical ﬁndings in VCFS/ analysis, we analyzed somatic hybrid cell lines that were
DGS. To identify candidate genes for VCFS, we have generated from three patients (BM26 and BM102 from
deﬁned the deletions among a large number of VCFS the report by Carlson et al. [1997] and BM75 from the
patients, have identiﬁed a new critical region for the present report), using STS markers across the 1,080-kb
interval, with an average between-marker spacing of 15disorder, and have isolated genes within the interval.
/ 9a35$$se17 09-02-97 18:27:24 ajhga UC-AJHG
627Carlson et al.: Molecular Deﬁnition of 22q11 Deletions
kb, but we did not ﬁnd a deletion. It is possible that HIRA (related to yeast repressors of histone-transcrip-
tion genes, HIR1 and HIR2; Halford et al. 1993a; La-these patients have a mutation in a critical gene located
in 22q11 or that a gene(s) elsewhere in the human ge- mour et al. 1995) and TMVCF (transmembrane protein
deleted in VCF; Sirotkin et al. 1997a). Several of thesenome is involved in the etiology. Genetic heterogeneity
for VCFS has been suggested (Greenberg et al. 1988; genes have been suggested to have a role in the etiology
of VCFS. GSCL is the second member of the goosecoidDaw et al. 1996). Alternatively, the nondeleted patients
are phenocopies with a teratogenic (Lammer and Opitz class of homeodomain-containing transcription factors
(Blum et al. 1992, 1994; Gottlieb et al. 1997; B. Funke,1986), maternal diabetes (Wilson et al. 1993), or other
fetal insult. B. Saint-Jore, A. Puech, H. Sirotkin, S. Raft, L. Edel-
mann, C. Carlson, et al., unpublished data). The GSCLThe most common deletion that we observed in the
VCFS patients maps to a 3-Mb region in 22q11, ﬂanked and goosecoid genes are members of the larger, Dro-
sophila bicoid gene family (Nusslein-Volhard et al.by the genetic markers D22S427 and D22S306/308. At
the resolution of the genetic markers, 90% of the VCFS 1987; Blum et al. 1992, 1994). The mouse goosecoid
homologue, located on human chromosome 14, haspatients with a detectable deletion had the same proxi-
mal and distal chromosomal breakpoints. Analysis of been inactivated by gene targeting, and the mice have
been shown to develop craniofacial and rib anomaliesthe individual copies of chromosome 22 in somatic hy-
brid cell lines from three patients, by means of STS (Rivera-Perez et al. 1995; Yamada et al. 1995). It is
possible that GSCL may also be involved in embryonicmarkers, conﬁrmed the ﬁnding derived by use of genetic
markers—that is, that the deletion breakpoints may be development. CLTD is highly homologous to the
clathrin heavy-chain gene located on chromosome 17within the same interval. These results suggest that se-
quences at these sites may be susceptible to chromo- (Sirotkin et al. 1996; Kedra et al. 1996). The CLTD
gene is expressed predominantly in adult skeletal musclesomal rearrangements. Molecular cloning and sequenc-
ing of these regions may reveal the basis for this (Sirotkin et al. 1996). A patient with some of the clinical
ﬁndings of VCFS/DGS was recently described to carry asusceptibility to breakage. A small proportion of the
patients have deletions that have the same proximal t(21;22) balanced translocation that disrupts the CLTD
gene, suggesting that CLTD may have a role in at leastbreakpoint as is seen for the 3-Mb deletion, but they
have a nested distal deletion chromosomal breakpoint some of the anomalies of VCFS (Holmes et al. 1997).
HIRA has signiﬁcant sequence homology with two re-resulting in a deletion that is estimated to 1.5 Mb. It
is possible that the D22S1623–D22S264 interval also pressors of histone gene transcription, HIR1 and HIR2,
in the yeast Saccharomyces cerevisiae (Lamour et al. 1995).contains sequences that confer susceptibility to rear-
rangement. The HIRA gene is expressed during mouse embryonic de-
velopment and, in particular, in the cephalic region of theDetailed analysis of several unique patients allowed
us to deﬁne a critical region for VCFS. The critical region embryo and the limb buds (Wilming et al. 1997). Expres-
sion studies in the chick have revealed expression in theis deﬁned by the breakpoints in patients G (Levy et al.
developing neural plate, neural tube, head mesenchyme,1995) and GM00980 (Fu et al. 1976; Halford et al.
and neural crest (Roberts et al. 1997). A newly described1993a). Examination of somatic hybrid cell lines from
gene, TMVCF, encodes a putative transmembrane proteinpatient G revealed that the proximal breakpoint in this
of unknown function (Sirotkin et al. 1997a). We havepatient is located between marker D22S1697 and the
identiﬁed six ESTs in the critical region, and they maycitrate-transport protein (CTP), which is deﬁned by
correspond to yet additional genes.D22S1621. This region is 120 kb distal to the balanced
Although the precise role of all of these genes is nottranslocation breakpoint in patient ADU (Budarf et al.
yet understood, the fact that they are always hemizygous1995). These results conﬁrm that the disruption of a
in VCFS patients carrying deletions suggests thatgene containing the ADU breakpoint is not directly re-
haploinsufﬁciency of one or more of these genes maysponsible for VCFS/DGS. The distal boundary of the
play a role in the etiology of the main clinical ﬁndingscritical region is deﬁned by the breakpoint in patient
of VCFS. Although the current effort is focused on iden-GM00980. We estimate the size of the critical region to
tiﬁcation of genes in the 480-kb critical region, it isbe 480 kb.
important to identify all of the genes encoded by the 3-The critical region deﬁned by us contains ﬁve genes
Mb region. Functional analysis of all of these genesand six ESTs. The genes are GSCL (goosecoid-like
would provide valuable clues to the full understanding[GSCL]; Gottlieb et al. 1997; B. Funke, B. Saint-Jore,
of all of the anomalies associated with VCFS.A. Puech, H. Sirotkin, S. Raft, L. Edelmann, C. Carlson,
et al., unpublished data), CTP (mitochondrial citrate-
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